New drug may reduce need for aortic valve surgeries by slowing disease progression
Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage AVS. Results from preclinical and clinical studies show that ataciguat has the potential to significantly slow disease progression.
